Jasper Therapeutics Inc. (JSPR) Stock Price, Quote & News

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic sp...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 549 1400

Website: jaspertx.com

Address:

2200 Bridge Pkwy, Suite 102, Redwood City, United States

FIREINSP Oct. 24 at 5:00 PM

$JSPR And of course it will close red, as per usual…

0 · Reply

Messerschmittbf109 Oct. 23 at 7:26 PM

$JSPR …

0 · Reply

Messerschmittbf109 Oct. 23 at 4:35 PM

$JSPR $CRVO bad strategy awful ….360 degrees

0 · Reply

Messerschmittbf109 Oct. 22 at 6:30 PM

$JSPR 😂🤣🤣🤣. Fraud stock

0 · Reply

VincentGogh Oct. 22 at 1:42 PM

$JSPR This is fun 😴😴😴

0 · Reply

USA_toinfinity_andbeyond Oct. 19 at 8:31 PM

Hype up! $JSPR is going up really soon!🚀💲💰

0 · Reply

Okadarlan Oct. 17 at 2:08 PM

$PRAX might aswell buy 5 lotto stocks that are down 90 % yoy and call it a day hahahaha. $PLRX $NMRA $JSPR $BMCA $MLTX

0 · Reply

Messerschmittbf109 Oct. 15 at 11:35 AM

$JSPR this board must be fired Shareholders need to make a class action Devastating strategy devastating incompetence devastating poor people Devastating low profile of rationality

0 · Reply

PremarketAnalysis Oct. 14 at 9:41 AM

$JSPR SignalEngine: Bullish 100/0, Algo Vol 43%, Org Vol 57%. Algo Int: holding tight range with iceberg activity near 2.4 zone, watching for lift confirmation. Momentum Feed: https://premarketanalysis.com/#momentum=JSPR

1 · Reply

jabcas Oct. 13 at 2:40 PM

$JSPR Just grabbed a starter pack. Seeing a little potential with this one. Not financial advice. Trading on emotions today. lol

0 · Reply

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Oct 12, 2025, 9:08 AM EDT - 13 days ago

JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Oct 10, 2025, 8:05 PM EDT - 14 days ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Sep 22, 2025, 1:05 PM EDT - 4 weeks ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)

Sep 19, 2025, 12:07 AM EDT - 5 weeks ago

Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Sep 18, 2025, 4:08 PM EDT - 5 weeks ago

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Aug 27, 2025, 4:30 PM EDT - 2 months ago

Jasper Therapeutics to Present at Upcoming Investor Conferences

Aug 13, 2025, 4:05 PM EDT - 2 months ago

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 11, 2025, 12:18 PM EDT - 3 months ago

JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Jul 9, 2025, 8:00 AM EDT - 3 months ago

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Jul 7, 2025, 1:25 PM EDT - 3 months ago

Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Jul 7, 2025, 7:30 AM EDT - 3 months ago

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jun 14, 2025, 10:00 AM EDT - 4 months ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jun 3, 2025, 8:00 AM EDT - 5 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

May 12, 2025, 4:05 PM EDT - 5 months ago

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 1, 2025, 12:45 PM EST - 8 months ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 8 months ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 27, 2025, 8:00 AM EST - 8 months ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 4:30 PM EST - 8 months ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 10, 2025, 8:00 AM EST - 9 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 4, 2025, 4:30 PM EST - 9 months ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 10 months ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 6, 2025, 8:00 AM EST - 10 months ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Dec 2, 2024, 4:30 PM EST - 11 months ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Nov 18, 2024, 10:09 AM EST - 1 year ago

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 13, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 14, 2024, 9:22 AM EDT - 1 year ago

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Sep 4, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Jun 19, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

Jun 17, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit

Jun 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress

May 30, 2024, 6:05 PM EDT - 1 year ago

Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

May 29, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments

May 13, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Briquilimab Development Program in Asthma

May 7, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at Upcoming Investor Conferences in May

Apr 2, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

FIREINSP Oct. 24 at 5:00 PM

$JSPR And of course it will close red, as per usual…

0 · Reply

Messerschmittbf109 Oct. 23 at 7:26 PM

$JSPR …

0 · Reply

Messerschmittbf109 Oct. 23 at 4:35 PM

$JSPR $CRVO bad strategy awful ….360 degrees

0 · Reply

Messerschmittbf109 Oct. 22 at 6:30 PM

$JSPR 😂🤣🤣🤣. Fraud stock

0 · Reply

VincentGogh Oct. 22 at 1:42 PM

$JSPR This is fun 😴😴😴

0 · Reply

USA_toinfinity_andbeyond Oct. 19 at 8:31 PM

Hype up! $JSPR is going up really soon!🚀💲💰

0 · Reply

Okadarlan Oct. 17 at 2:08 PM

$PRAX might aswell buy 5 lotto stocks that are down 90 % yoy and call it a day hahahaha. $PLRX $NMRA $JSPR $BMCA $MLTX

0 · Reply

Messerschmittbf109 Oct. 15 at 11:35 AM

$JSPR this board must be fired Shareholders need to make a class action Devastating strategy devastating incompetence devastating poor people Devastating low profile of rationality

0 · Reply

PremarketAnalysis Oct. 14 at 9:41 AM

1 · Reply

jabcas Oct. 13 at 2:40 PM

$JSPR Just grabbed a starter pack. Seeing a little potential with this one. Not financial advice. Trading on emotions today. lol

0 · Reply

Messerschmittbf109 Oct. 13 at 2:25 PM

$JSPR eye for their spit 👀 Vomiting board

0 · Reply

Bullshyte Oct. 9 at 7:44 PM

$JSPR By christ, when this pops, it will POPPPPP!!!!!

1 · Reply

LORAXX Oct. 9 at 7:11 PM

$JSPR Ripe and ready. Has been accumulated BIG since October 1st. I'm buckled in and ready. Are you?

0 · Reply

PremarketAnalysis Oct. 9 at 7:05 PM

$JSPR regaining strength after recent compression phase. SignalEngine: Bullish 100/0, Algo Vol 46%, Organic Vol 54%, BRX 35%. Algo Intent: steady volume rotation, reclaiming prior range support with momentum lift. Momentum Feed: premarketanalysis.com/#momentum=JSPR

0 · Reply

JValis Oct. 9 at 6:11 PM

$JSPR 🤩

0 · Reply

Messerschmittbf109 Oct. 9 at 5:06 PM

$CRVO $SBET $JSPR coffee shop stocks Only vacuums

0 · Reply

FIREINSP Oct. 8 at 1:17 PM

$JSPR Can we finally get this pig to finally take off???

1 · Reply

Messerschmittbf109 Oct. 6 at 5:45 PM

$CRVO $JSPR $VYNE bets themselves

0 · Reply

Messerschmittbf109 Oct. 6 at 5:45 PM

$CRVO rottens $JSPR $VYNE Rottens and bets

0 · Reply

Messerschmittbf109 Oct. 6 at 3:32 PM

$JSPR eye 👁️ for spit on each other

0 · Reply

RiskyKev Oct. 5 at 8:50 AM

$JSPR Biotech with clinical catalyst. High short interest. Volatility compression suggests large move imminent. High risk setup.

0 · Reply

LORAXX Oct. 3 at 2:22 PM

$JSPR A lot of accumulation happening according to the A/D technical. Sure seems somebody knows something. Cheers Bulls!

0 · Reply

Market Cap	37.87M
Revenue (ttm)	0.00
Net Income (ttm)	-71.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	775,600
Avg Vol	331,958
Day's Range	N/A - N/A
Shares Out	16.25M
Stochastic %K	18%
Beta	2.79
Analysts	Strong Sell
Price Target	$10.71